Abraham Pinter - Publications

Affiliations: 
New York University, New York, NY, United States 
Area:
Molecular Biology, Microbiology Biology

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, et al. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. The Journal of Clinical Investigation. 124: 3879-90. PMID 25105367 DOI: 10.1172/JCI75539  0.44
2014 Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, ... ... Pinter A, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Science Translational Medicine. 6: 228ra39. PMID 24648342 DOI: 10.1126/scitranslmed.3007730  0.44
2014 Jalah R, Kulkarni V, Patel V, Rosati M, Alicea C, Bear J, Yu L, Guan Y, Shen X, Tomaras GD, LaBranche C, Montefiori DC, Prattipati R, Pinter A, Bess J, et al. DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques. Plos One. 9: e91550. PMID 24626482 DOI: 10.1371/journal.pone.0091550  0.44
2014 Shmelkov E, Krachmarov C, Grigoryan AV, Pinter A, Statnikov A, Cardozo T. Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies. Plos One. 9: e89987. PMID 24587168 DOI: 10.1371/journal.pone.0089987  0.44
2014 Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. Plos One. 9: e87572. PMID 24504509 DOI: 10.1371/journal.pone.0087572  0.44
2014 Salomon A, Krachmarov C, Lai Z, Honnen W, Zingman BS, Sarlo J, Gorny MK, Zolla-Pazner S, Robinson JE, Pinter A. Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking. Virology. 448: 363-74. PMID 24314667 DOI: 10.1016/j.virol.2013.10.007  0.44
2013 Kulkarni V, Rosati M, Valentin A, Jalah R, Alicea C, Yu L, Guan Y, Shen X, Tomaras GD, LaBranche C, Montefiori DC, Irene C, Prattipati R, Pinter A, Sullivan SM, et al. Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. Human Vaccines & Immunotherapeutics. 9: 2069-80. PMID 23820294 DOI: 10.4161/hv.25442  0.44
2013 Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E, Berman P, Shen X, Andrews C, O'Connell RJ, Ngauy V, ... ... Pinter A, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. Plos One. 8: e53629. PMID 23349725 DOI: 10.1371/journal.pone.0053629  0.44
2013 Liao HX, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang KK, Chen X, Tsao CY, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, ... ... Pinter A, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 38: 176-86. PMID 23313589 DOI: 10.1016/j.immuni.2012.11.011  0.44
2012 Basu D, Kraft CS, Murphy MK, Campbell PJ, Yu T, Hraber PT, Irene C, Pinter A, Chomba E, Mulenga J, Kilembe W, Allen SA, Derdeyn CA, Hunter E. HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection. Retrovirology. 9: 76. PMID 22995123 DOI: 10.1186/1742-4690-9-76  0.44
2012 Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. The New England Journal of Medicine. 366: 1275-86. PMID 22475592 DOI: 10.1056/NEJMoa1113425  0.44
2011 Krachmarov C, Lai Z, Honnen WJ, Salomon A, Gorny MK, Zolla-Pazner S, Robinson J, Pinter A. Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities. Journal of Virology. 85: 10730-40. PMID 21835798 DOI: 10.1128/JVI.00365-11  0.44
2011 Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, Honnen WJ, Nonyane M, Tumba N, Hermanus T, Sibeko S, Mlisana K, Abdool Karim SS, Williamson C, Pinter A, et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. Journal of Virology. 85: 3128-41. PMID 21270156 DOI: 10.1128/JVI.02658-10  0.44
2011 Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, Salomon A, Williams C, Seaman MS, Abagyan R, Cardozo T, Gorny MK, Wang S, Lu S, Pinter A, Zolla-Pazner S. Corrigendum to Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold" [Virology 351 (2010) 513-523] Virology. 409: 360. DOI: 10.1016/j.virol.2010.11.003  0.44
2010 Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, Salomon A, Williams C, Seaman MS, Abagyan R, Cardozo T, Gorny MK, Wang S, Lu S, Pinter A, Zolla-Pazner S. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology. 405: 513-23. PMID 20663531 DOI: 10.1016/j.virol.2010.06.027  0.44
2010 Lynch RM, Rong R, Li B, Shen T, Honnen W, Mulenga J, Allen S, Pinter A, Gnanakaran S, Derdeyn CA. Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. Virology. 404: 59-70. PMID 20494390 DOI: 10.1016/j.virol.2010.04.010  0.44
2009 Granados-Gonzalez V, Piedrahita LD, Martinez-Gutierrez M, Lawrence P, Saoudin H, Zapata X, Lucht F, Pinter A, Genin C, Urcuqui-Inchima S, Riffard S. Neutralizing inter-clade cross-reactivity of HIV-1 V1/V2-specific secretory immunoglobulin A in Colombian and French cohorts. Aids (London, England). 23: 2219-22. PMID 19830891  0.44
2009 Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, Robinson JE, Gnanakaran S, Derdeyn CA. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. Plos Pathogens. 5: e1000594. PMID 19763269 DOI: 10.1371/journal.ppat.1000594  0.44
2009 Zolla-Pazner S, Cohen S, Pinter A, Krachmarov C, Wrin T, Wang S, Lu S. Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology. 392: 82-93. PMID 19632700 DOI: 10.1016/j.virol.2009.05.039  0.44
2009 Cardozo T, Swetnam J, Pinter A, Krachmarov C, Nadas A, Almond D, Zolla-Pazner S. Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies. Aids Research and Human Retroviruses. 25: 441-50. PMID 19320565 DOI: 10.1089/aid.2008.0188  0.44
2009 Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology. 387: 414-26. PMID 19298995 DOI: 10.1016/j.virol.2009.02.022  0.44
2009 Davis KL, Bibollet-Ruche F, Li H, Decker JM, Kutsch O, Morris L, Salomon A, Pinter A, Hoxie JA, Hahn BH, Kwong PD, Shaw GM. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. Journal of Virology. 83: 1240-59. PMID 19019969 DOI: 10.1128/JVI.01743-08  0.44
2009 Gorny MK, Wang XH, Williams C, Volsky B, Revesz K, Witover B, Burda S, Urbanski M, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S, Nadas A. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Molecular Immunology. 46: 917-26. PMID 18952295 DOI: 10.1016/j.molimm.2008.09.005  0.44
2009 Totrov M, Jiang X, Kong X, Cohen S, Krachmarov C, Williams C, Cardozo T, Gorny M, Wang S, Lu S, Pinter A, Zolla-Pazner S. P12-13. Structure-guided design and immunological characterization of immunogen constructs presenting the HIV-1 gp120 V3 loop on a CTB scaffold Retrovirology. 6: P179. DOI: 10.1186/1742-4690-6-S3-P179  0.44
2009 Rong R, Li B, Haaland RE, Murphy MK, Mulenga J, Allen SA, Blackwell JL, Pinter A, Shaw GM, Gnanakaran S, Hunter E, Robinson JE, Derdeyn CA. P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape Retrovirology. 6: P125. DOI: 10.1186/1742-4690-6-S3-P125  0.44
2009 Zolla-Pazner S, Kong X, Cardozo T, Hioe C, Cohen S, Jiang X, Gorny MK, Totrov M, Pinter A, Krachmarov C, Seaman MS, Wang S, Lu S. P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope Retrovirology. 6: P37.  0.44
2008 Zolla-Pazner S, Cohen SS, Krachmarov C, Wang S, Pinter A, Lu S. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology. 372: 233-46. PMID 18061228 DOI: 10.1016/j.virol.2007.09.024  0.44
2007 Wilkinson RA, Evans JR, Jacobs JM, Slunaker D, Pincus SH, Pinter A, Parkos CA, Burritt JB, Teintze M. Peptides selected from a phage display library with an HIV-neutralizing antibody elicit antibodies to HIV gp120 in rabbits, but not to the same epitope. Aids Research and Human Retroviruses. 23: 1416-27. PMID 18184085 DOI: 10.1089/aid.2007.0027  0.44
2006 Krachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S, Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. Journal of Virology. 80: 7127-35. PMID 16809318 DOI: 10.1128/JVI.02619-05  0.44
2006 Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, Kimura T, Konings FA, Nádas A, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. Journal of Virology. 80: 6865-72. PMID 16809292 DOI: 10.1128/JVI.02202-05  0.44
2005 Tuen M, Visciano ML, Chien PC, Cohen S, Chen PD, Robinson J, He Y, Pinter A, Gorny MK, Hioe CE. Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. European Journal of Immunology. 35: 2541-51. PMID 16106369 DOI: 10.1002/eji.200425859  0.44
2005 Burkhart MD, D'Agostino P, Kayman SC, Pinter A. Involvement of the C-terminal disulfide-bonded loop of murine leukemia virus SU protein in a postbinding step critical for viral entry. Journal of Virology. 79: 7868-76. PMID 15919941 DOI: 10.1128/JVI.79.12.7868-7876.2005  0.44
2005 Pinter A, Honnen WJ, D'Agostino P, Gorny MK, Zolla-Pazner S, Kayman SC. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. Journal of Virology. 79: 6909-17. PMID 15890930 DOI: 10.1128/JVI.79.11.6909-6917.2005  0.44
2005 Krachmarov C, Pinter A, Honnen WJ, Gorny MK, Nyambi PN, Zolla-Pazner S, Kayman SC. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. Journal of Virology. 79: 780-90. PMID 15613306 DOI: 10.1128/JVI.79.2.780-790.2005  0.44
2004 Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. Journal of Virology. 78: 5205-15. PMID 15113902 DOI: 10.1128/JVI.78.10.5205-5215.2004  0.44
2004 Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. Journal of Virology. 78: 2394-404. PMID 14963135 DOI: 10.1128/JVI.78.5.2394-2404.2004  0.44
2003 He Y, D'Agostino P, Pinter A. Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. Vaccine. 21: 4421-9. PMID 14505925  0.44
2003 Burkhart MD, Kayman SC, He Y, Pinter A. Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU. Journal of Virology. 77: 3993-4003. PMID 12634359  0.44
2002 Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, Polonis VR, Honnen WJ, Kayman SC, Krachmarov C, Pinter A, Zolla-Pazner S. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. Journal of Virology. 76: 9035-45. PMID 12186887 DOI: 10.1128/JVI.76.18.9035-9045.2002  0.44
2002 He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J, Pinter A. Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. Journal of Immunology (Baltimore, Md. : 1950). 169: 595-605. PMID 12077293  0.44
Show low-probability matches.